Buy­out Buzz: Sanofi, Gilead ru­mors keep the fire burn­ing un­der a boil­ing Tesaro buy­out sto­ry

At this stage, there may be a few peo­ple left in bio­phar­ma who haven’t heard that Tesaro $TSRO has re­port­ed­ly set it­self up on the auc­tion block in search of a nice, fat buy­out of­fer. For those who like to keep tabs on M&A, we of­fer the lat­est word from StreetInsid­er that Sanofi $SNY is kick­ing the tires and talk­ing price — which may start around $10 bil­lion, or $185 a share.

But the plot thick­ens with word that Gilead — an­oth­er deep pock­et play­er with big am­bi­tions — may al­so be look­ing to jump in­to the game.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER